Former Dallas Mavericks forward Dirk Nowitzki broke down one of the plays that he and his team adopted to adapt to new ...

According to Bron, this playstyle originated with the "Seven Seconds or Less" Suns and Tim Duncan's San Antonio Spurs toward ...

Meg James is a senior entertainment industry writer for the Los Angeles Times. She was the lead reporter for The Times’ coverage of the deadly “Rust” shooting on a New Mexico film set in ...

Editorial writer and columnist specializing in domestic policy and politics James Hohmann is a Washington Post editorial writer and columnist specializing in domestic policy and politics.

The road to the development of treatments for non-alcoholic steatohepatitis (NASH) is littered with failed projects, but US biotech Madrigal Pharma thinks it now has enough evidence for its drug ...

If you buy something, we may earn an affiliate commission. This is GQ's power ranking of the prime candidates to be the next James Bond, which is updated regularly — and will be until an ...

Inventiva’s lanifibranor has been tipped to become a blockbuster in the fatty liver disease non-alcoholic steatohepatitis (NASH) after it became the first drug to hit two regulatory goals in a ...

The gunman, Vester Lee Flanagan, shot himself after a highway chase. Also, James Holmes… Judge sentences James Holmes to life in prison A judge formally sentenced James Holmes, who shot and ...

In a transformative donation, the Clark Art Institute in Williamstown, Massachusetts, has received a gift from the Aso O. Tavitian Foundation of 331 works of art. The fact that the Imperial War Museum ...

Around this time last year, Akero was riding high on positive phase 2b data for its candidate non-alcoholic steatohepatitis (NASH) therapy, but new data has dented optimism about the project.

Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.

CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), ending development of its lead drug.